Navid Sobhani
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer-related Molecular Pathways
- Cancer Research top 10%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 29
- Cancer Immunotherapy and Biomarkers 11
- Cancer-related Molecular Pathways 7
-
- Advanced Breast Cancer Therapies 8
- Prostate Cancer Treatment and Research 5
- Co-authors
- Giandomenico Roviello (22 shared papers)Alberto D’Angelo (25 shared papers)Daniele Generali (23 shared papers)Yong Li (8 shared papers)Daniele Generali (11 shared papers)Raheleh Roudi (12 shared papers)Silvia Paola Corona (12 shared papers)Fabrizio Zanconati (12 shared papers)
- Journals
- Cancers (11 papers)International Journal of Molecular Sciences (4 papers)Cells (3 papers)iScience (2 papers)Investigational New Drugs (2 papers)
- Partner nations
- ItalyUnited StatesUnited Kingdom
In The Last Decade
Navid Sobhani
56 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 100
- Oncology 607
- Cancer Research 249
- Immunology 294
- Pulmonary and Respiratory Medicine 416
- Molecular Biology 556
Countries citing papers authored by Navid Sobhani
This map shows the geographic impact of Navid Sobhani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Navid Sobhani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Navid Sobhani more than expected).
Fields of papers citing papers by Navid Sobhani
This network shows the impact of papers produced by Navid Sobhani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Navid Sobhani. The network helps show where Navid Sobhani may publish in the future.
Co-authors
The 25 scholars most cited alongside Navid Sobhani, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 58 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 181 | |
| 2 | 2019 | 119 | |
| 3 | 2018 | 77 | |
| 4 | 2011 | 74 | |
| 5 | 2020 | 70 | |
| 6 | The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects Hit paper breakdown → | 2024 | 69 |
| 7 | 2022 | 58 | |
| 8 | 2020 | 48 | |
| 9 | 2021 | 45 | |
| 10 | 2021 | 39 | |
| 11 | 2021 | 39 | |
| 12 | 2018 | 36 | |
| 13 | 2017 | 31 | |
| 14 | 2019 | 28 | |
| 15 | 2018 | 28 | |
| 16 | 2021 | 26 | |
| 17 | 2019 | 21 | |
| 18 | 2022 | 21 | |
| 19 | 2018 | 21 | |
| 20 | 2018 | 20 |
About Navid Sobhani
Navid Sobhani is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Immunology and Cancer Research, having authored 58 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (9 papers), Advanced Breast Cancer Therapies (8 papers), Cancer Genomics and Diagnostics (7 papers), Cancer-related Molecular Pathways (7 papers), Prostate Cancer Treatment and Research (5 papers), Cancer Research and Treatments (4 papers) and Immune Cell Function and Interaction (4 papers). The work is most often cited by research in Oncology (607 citations), Cancer Research (249 citations), Immunology (294 citations), Pulmonary and Respiratory Medicine (416 citations) and Molecular Biology (556 citations). Navid Sobhani has collaborated with scholars based in Italy, United States and United Kingdom. Frequent co-authors include Giandomenico Roviello, Alberto D’Angelo, Daniele Generali, Yong Li, Daniele Generali, Raheleh Roudi, Silvia Paola Corona, Fabrizio Zanconati, Aram Davtyan and Marina Bortul. Their work appears in journals such as Cancers, International Journal of Molecular Sciences, Cells, iScience and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.